For Healthcare Professionals

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial


About the study

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: What side effects may happen from taking the study drug How much study drug is in your blood at different times How much the study drug improves quality of life and mental health

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Skin of color, defined as Fitzpatrick skin type ≥4 at screening visit
  2. Diagnosis of moderate-to-severe atopic dermatitis (AD) that cannot be adequately controlled with topical AD medications, as defined in protocol
  3. Has applied a stable dose of topical emollient (moisturizer) twice daily as per physician recommendation starting at screening visit


Key Exclusion Criteria:

  1. Self-reported Caucasian or White race
  2. Adolescent body weight less than 30 kg at screening
  3. Prior use of dupilumab within 6 months of screening
  4. Concomitant skin diseases or other pigmentary disorder that could confound AD assessments
  5. Current or prior use, within 12 weeks before the screening visit, of phototherapy or tanning beds
  6. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline
  7. Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 7 days prior to baseline
  8. Planned or anticipated use of any prohibited medications and procedures, as defined in protocol
  9. Has received a COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study drug

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Moderate-to-Severe Atopic Dermatitis,Atopic Eczema

Age (in years)



Phase 4

Participants needed


Est. Completion Date

Jul 23, 2025

Treatment type



Regeneron Pharmaceuticals identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.